THERANEXUS news, videos and press releases
For more news please use our advanced search feature.
THERANEXUS - More news...
THERANEXUS - More news...
- THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
- Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
- Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
- THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN
- THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS
- THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023
- Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1
- THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS
- Theranexus raises around 3.1 million euros in fundraising
- Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)
- CORRECTION FROM SOURCE: Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease
- Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to evaluate Batten-1 in CLN3 Batten disease
- Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease
- THERANEXUS PUBLISHES ITS 2022 FULL-YEAR RESULTS AND PRESENTS AN UPDATE ON ITS PROGRAMS
- THERANEXUS, BBDF AND CARDIFF UNIVERSITY PRESENT THEIR NOVEL RESEARCH ON BATTEN-1 AND BATTEN DISEASE AT WORLDSYMPOSIUM 2023
- AISTROSIGHT: NEW JOINT PROJECT TEAM BETWEEN THERANEXUS, INRIA, CLAUDE BERNARD UNIVERSITY LYON 1 AND HOSPICES CIVILS DE LYON TARGETING RARE NEUROLOGICAL DISEASES
- THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES
- New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)
- New Advance to the Theranexus and BBDF Batten-1 Program for Juvenile Batten Disease (CLN3)
- THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2023
- THERANEXUS ANNOUNCES PARTICIPATION IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9-12, 2023 IN SAN FRANCISCO
- THERANEXUS AND BBDF PRESENT PROGRESS ON THE BATTEN-1 PROGRAM AT THE TRANSLATIONAL RESEARCH CONFERENCE FOR THE MANAGEMENT OF NCLS ON 3 AND 4 NOVEMBER, 2022 IN CHICAGO
- THERANEXUS AND INSERM TRANSFERT SIGN A STRATEGIC ALLIANCE TO IDENTIFY ADVANCED THERAPY DRUG CANDIDATES FOR RARE NEUROLOGICAL DISEASES
- Theranexus publishes its cash position as of 30 September 2022
- THERANEXUS ANNOUNCES ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2022
- Theranexus and BBDF finalize recruitment for phase I/II trial to evaluate Batten-1 in Batten disease
- Theranexus publishes its cash position as of 30 june 2022
- THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS
- Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
- Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases